Pravastatin reduces fibrinogen receptor gpIIIa on platelet-derived microparticles in patients with type 2 diabetes

J Thromb Haemost. 2005 Jun;3(6):1168-71. doi: 10.1111/j.1538-7836.2005.01403.x.
No abstract available

Publication types

  • Clinical Trial
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Blood Platelets / ultrastructure*
  • Cholesterol / blood
  • Cross-Over Studies
  • Diabetes Mellitus, Type 2 / blood*
  • Female
  • Humans
  • Integrin beta3 / analysis
  • Integrin beta3 / drug effects*
  • Macromolecular Substances / blood
  • Macromolecular Substances / chemistry*
  • Male
  • Middle Aged
  • Platelet Activation
  • Pravastatin / pharmacology*
  • Pravastatin / therapeutic use

Substances

  • Integrin beta3
  • Macromolecular Substances
  • Cholesterol
  • Pravastatin